The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 661-671 , October 2008

Translating ADA/EASD Guidelines and the ACE/AACE Road Maps into Primary Care of Patients with Type 2 Diabetes

  • Carolyn Robertson

      Affiliations

    • Carolyn Robertson, APRN, MSN, CS, BC-ADM, CDE, is a Clinical Nurse Specialist at the Gonda Diabetes Center at the University of California at Los Angeles.

References 

  1. Goldfarb B . ACE and AACE Issue Treat-to-Target road map . DOC News . 2005;2:11
  2. Centers for Disease Control and Prevention  . National diabetes fact sheet: general information and national estimates on diabetes in the United States . Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2007; 2007
  3. National Institute of Diabetes and Digestive and Kidney Diseases  . National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States . Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2007; Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed August 4, 2008.
  4. Saydah SH , Fradkin J , Cowie CC . Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes . JAMA . 2004;291:335–342
  5. American Diabetes Association  . Standards of Medical Care in Diabetes – 2008 . Diabetes Care . 2008;31(Suppl 1):S13–S54
  6. Lebovitz HE , Austin MM , Blonde L , et al.   ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations . Endocr Pract . 2006;12(Suppl 1):6–12
  7. Davis WA , Bruce DG , Davis T . Is self monitoring of blood glucose appropriate for all Type 2 diabetic patients? The Fremantle diabetes study . Diabetes Care . 2006;29:1764–1770
  8. Nathan DM , Buse JB , Davidson MB , et al.   Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy . Diabetes Care . 2006;29:1963–1972
  9. Jellinger PS , Davidson JA , Blonde L , et al.   Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force . Endocr Pract . 2007;13:260–268
  10. The United Kingdom Prospective Diabetes Study Group  . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes . Lancet . 1998;352:837–853
  11. The United Kingdom Prospective Diabetes Study Group  . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes . Lancet . 1998;352:854–865
  12. Stratton IM , Adler AI , Neil HA , et al.   Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) . BMJ . 2000;321:405–412
  13. Tuomilehto J , Lindstrom J , Eriksson JG , et al.   (Finnish Diabetes Prevention Study Group). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance . N Engl J Med . 2001;344:1343–1350
  14. Knowler WC , Barratt-Connor E , Fowler SE , et al.   Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin . N Engl J Med . 2002;346:393–403
  15. Monnier L , Lapinski H , Colette C . Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c) . Diabetes Care . 2003;26:881–885
  16. DECODE Study Group  , European Diabetes Epidemiology Group  . Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? . Diabetes Care . 2003;26:688–696
  17. Esposito K , Giugliano D , Nappo F , et al.   Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus . Circulation . 2004;110:214–219
  18. Genuth S . Insights from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study on the use of intensive glycemic treatment to reduce the risk of complications of type I diabetes . Endocr Pract . 2006;12(Suppl 1):34–41
  19. Hanefeld M , Koehler C , Schaper F , et al.   Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals . Atherosclerosis . 1999;144:229–235
  20. Hanefeld M , Temelkova-Kurktschiev T . Control of post-prandial hyperglycemia – an essential part of good diabetes treatment and prevention of cardiovascular complications . Nutr Metab Cardiovasc Dis . 2002;12:98–107
  21. Nathan DM , Cleary PA , Cacklund JY , et al.   Intensive diabetes treatment and cardiovascular disease in patients with type I diabetes . N Engl J Med . 2005;353:2642–2653
  22. Ohkubo Y , Kishikawa H , Araki E , et al.   Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomizedprospective 6-year study . Diabetes Res Clin Pract . 1995;28:103–117
  23. Khaw KT , Wareham N , Luben R , et al.   Glycated haemoglobin, diabetes, and mortality in men in the Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) . BMJ . 2000;322:15–18
  24. Nissen SE , Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes . N Engl J Med . 2007;356:2457–2471
  25. Lincoff M , Wolski K , Nicholls SJ , Nissen SE . Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials . JAMA . 2007;298:1180–1188
  26. Singh S , Loke YK , Furberg CD . Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis . JAMA . 2007;298:1189–1195
  27. Solomon DH , Winkelmayer WC . Cardiovascular risk and the thiazolidinediones: déjà vu all over again? . JAMA . 2007;298:1216–1218
  28. Lago RM , Singh P , Nesto R . Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials . Lancet . 2007;370:1129–1136
  29. Home PD , Pocock SJ , Beck-Nielsen H , et al. , for the RECORD Study Group    Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis . N Engl J Med . 2007;357:28–38
  30. Siebolds M , Gaedeke O , Schwede U . Self-monitoring of blood glucose – psychological aspects relevant to changes in HbA1c in type 2 diabetic patients treated with diet or diet plus oral antidiabetic medication . Patient Educ. Couns. . 2006;62:104–110
  31. Welschen LMC , Bloemendal E , Nijpels G , et al.   Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin . Cochrane Database of Syst Rev . 2005; Issue 3. Art. No.: CD005060
  32. Schwedes U , Siebolds M , Mertes G . Meal-related structured self-monitoring of blood glucose: effect on diabetes control in non-insulin-treated type 2 diabetic patients . Diabetes Care . 2002;25:1928–1932
  33. Rohlfing CL , Wiedmeyer HM , Little RR , et al.   Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications Trial . Diabetes Care . 2002;25:275–278
  34. American Diabetes Association  . Postprandial blood glucose (Consensus Statement) . Diabetes Care . 2001;24:775–778
  35. Meneghini LF , Rosenberg KH , Koenen C , et al.   Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study . Diabetes Obes Metab . 2007;9:418–427
  36. Hirsch IB . Type 1 diabetes mellitus and the use of flexible insulin regimens . Am Fam Physician . 1999;60:2343–2352 2355-2356.
  37. Hermansen K , Fontaine P , Kukolja KK , et al.   Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes . Diabetologia . 2004;47:622–629
  38. Raslova K , Tamer SC , Clauson P , et al.   Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index . Clin Drug Investig . 2007;27:279–285
  39. Home P , Kurtzhals P . Insulin detemir: from concept to clinical experience . Expert Opin Pharmacother . 2006;7:325–343
  40. Riddle MC , Rosenstock J , Gerich J . The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients . Diabetes Care . 2003;26:3080–3086
  41. Kulzer B , Hermanns N , Reinecker H , Haak T . Effects of self-management training in type 2 diabetes: a randomized, prospective trial . Diabet Med . 2007;24:415–423
  42. Jorgens V . [Cost-benefit analysis of education programs and of treatment in type 2 diabetes] [Article in French] . Diabetes Metab . 1993;19(5 Suppl):510–513
  43. Strine TW , Okoro CA , Chapman DP , et al.   The impact of formal diabetes education on the preventive health practices and behaviors of persons with type 2 diabetes . Prev Med . 2005;41:79–84
  44. Deakin T , McShane CE , Cade JE , Williams RD . Group based training for self-management strategies in people with type 2 diabetes mellitus . Cochrane Database Syst Rev . 2005;(2): CD003417.
  45. Ko SH , Song KH , Kim SR , et al.   Long-term effects of a structured intensive diabetes education programme (SIDEP) in patients with type 2 diabetes mellitus – a 4-year follow-up study . Diabet Med . 2007;24:55–62
  46. Wagner EH . Chronic disease management: what will it take to improve care for chronic illness? . Eff Clin Pract . 1998;1:2–4
  47. Wagner EH , Austin BT , Davis C , et al.   Improving chronic illness care: translating evidence into action . Health Aff (Millwood) . 2001;20:64–78 Gerstein HC , Yusuf S , Bosch J , et al.   Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial . Lancet . 2006;368:1096–1105

 In compliance with national ethical guidelines, the author reports that editing assistance was provided by Bioscript Stirling Limited, UK, funded by NovoNordisk; however, she did not receive financial support and there is no arrangement that would represent conflict of interest.

PII: S1555-4155(08)00005-6

doi: 10.1016/j.nurpra.2008.01.016

The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 661-671 , October 2008

Article Tools

* Image Usage & Resolution